pamidronate has been researched along with Breast Neoplasms in 237 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases." | 9.22 | A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. ( Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S, 2016) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 9.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 9.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 9.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 9.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 9.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "We studied women with metastatic breast cancer receiving zoledronic acid or pamidronate disodium to reduce the incidence of skeletal-related events (SREs)." | 9.11 | Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. ( Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP, 2004) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 9.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "The study was a 1-yr randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer." | 9.11 | Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. ( Chehal, A; Fuleihan, Gel-H; Mahfoud, Z; Mourad, YA; Salamoun, M; Salem, Z; Shamseddine, A, 2005) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 9.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Results of a large, randomized, comparative phase III trial involving 1,130 breast cancer patients demonstrated that 4 mg zoledronic acid and 90 mg pamidronate were equally effective at reducing the occurrence and delaying the onset of skeletal-related events in patients with bone metastases secondary to breast cancer." | 9.10 | Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. ( Coleman, RE, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 9.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 9.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 9.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 9.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "The effect of pamidronate treatment on the first development of bone metastases was investigated in 124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal metastases (n = 91), but no bone metastases in a randomised, multicentre, open controlled study." | 9.08 | Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? ( Beex, LV; Blijham, G; Cleton, FJ; Hermans, J; Papapoulos, SE; Sleeboom, HP; van Eck-Smit, BC; van Holten-Verzantvoort, AT, 1996) |
| "Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients)." | 9.08 | Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. ( Bonneterre, J; Calabresi, F; Campos, D; Conte, PF; Ford, JM; Francini, G; Latreille, J; Mauriac, L; Santos, R, 1996) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 9.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 9.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 9.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 9.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "An open, randomized study was performed to assess the effects of supportive pamidronate treatment on morbidity from bone metastases in breast cancer patients." | 9.07 | Palliative pamidronate treatment in patients with bone metastases from breast cancer. ( Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 9.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 9.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormonetherapy." | 9.07 | Disodium pamidronate in the treatment of bone metastases from breast cancer. ( Bajetta, E; Bochicchio, AM; Colleoni, M; Nolè, F, 1993) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 9.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "The American Society of Clinical Oncology recommends bisphosphonate use, such as intravenous pamidronate, for women with breast cancer who have radiographic evidence of bone destruction." | 8.85 | Pamidronate-induced kidney injury in a patient with metastatic breast cancer. ( Nagahama, M; Sica, DA, 2009) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 7.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 7.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 7.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "To estimate the costs and consequences of using pamidronate compared to zoledronic acid in the prophylactic management of skeletal morbidity among breast cancer patients in the UK." | 7.73 | Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. ( Clegg, JP; Davie, AM; Guest, JF; McCloskey, E, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 7.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "The aim of this study was to compare the cost-effectiveness of oral ibandronate with zoledronic acid and generic pamidronate (both administered by IV) for the treatment of bone metastases in patients with breast cancer receiving oral hormonal therapy in the United Kingdom." | 7.73 | Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "The Japanese Ministry of Health, Labor and Welfare approved the use of pamidronate in November 2004 at a dose of 90 mg/day/month especially for Japanese breast cancer patients with lytic bone metastasis." | 7.73 | [Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis]. ( Aogi, K; Ohsumi, S; Okita, A; Taira, N; Takashima, S, 2006) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 7.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase." | 7.72 | Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004) |
| "Our goal was to evaluate the impact of pamidronate therapy on medical resource utilization for treatment of bone metastases among patients with breast cancer." | 7.71 | The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. ( Ackerman, SJ; Beusterien, KM; Hill, MC; Zacker, C, 2001) |
| "Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions." | 7.70 | Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. ( Desch, CE; Hillner, BE; Smith, TJ; Weeks, JC, 2000) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 7.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| "The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally." | 7.68 | The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. ( Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 7.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "The bisphosphonate pamidronate (3 amino-1, 1-hydroxypropylidene bisphosphonate (APD), Ciba-Geigy) is a powerful inhibitor of osteoclast function and has been shown to significantly reduce osteolysis associated with bone metastases in breast cancer." | 7.68 | Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. ( Dodwell, DJ; Ford, J; Howell, A, 1990) |
| "Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval." | 6.78 | Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. ( Amir, E; Carlsson, L; Clemons, M; Dranitsaris, G; Freedman, O; Laupacis, A; Tannock, IF; Tomlinson, G, 2013) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 6.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 6.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "Pamidronate is a potent biphosphonate which modulates tumour-induced osteolysis (TIO) by inhibiting osteoclast-mediated bone resorption." | 6.68 | Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. ( Bruning, PF; Ford, JM; Mauriac, L; May-Levin, F; Rose, C; Soukop, M; Tyrrell, CT, 1995) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 6.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 6.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "A 15 minute infusion of 4 mg of zoledronic acid is at least as effective as 90 mg of pamidronate in preventing skeletal complications in patients with metastatic breast cancer." | 6.20 | Bisphosphonates and metastatic breast carcinoma. ( Lipton, A, 2003) |
| "Human breast cancer is among one major health concerns with high prevalence and mortality among women worldwide." | 5.91 | Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics. ( Ahmed, A; Hashim, Z; Ilyas, A; Syed, B; Syed, N; Zarina, S, 2023) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 5.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| "Human breast cancer is a major cause of global morbidity and mortality in women and it is a process that involves numerous molecular and cellular alterations attributed to environmental substances and agents such as hormones." | 5.42 | Antitumor activity of pamidronate in breast cancer cells transformed by low doses of α-particles and estrogen in vitro. ( Calaf, GM; Ponce-Cusi, R, 2015) |
| "Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases." | 5.31 | Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. ( Appel, GB; D'Agati, VD; Dratch, AD; Fenves, AZ; Fine, PL; Jagannath, S; Kuhn, JA; Loon, NR; Markowitz, GS, 2001) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 5.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 5.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases." | 5.22 | A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. ( Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S, 2016) |
| " This model was applied to the placebo-control arm of a pamidronate study in patients with malignant bone disease from breast cancer." | 5.14 | Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, PP; Smith, MR; Terpos, E, 2009) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 5.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate." | 5.13 | A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. ( Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 5.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 5.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 5.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 5.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "We studied women with metastatic breast cancer receiving zoledronic acid or pamidronate disodium to reduce the incidence of skeletal-related events (SREs)." | 5.11 | Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. ( Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP, 2004) |
| "Data concerning the suspension of new skeletal complications, as well as the apparent improvement of overall survival, pain score and ECOG status, suggest that the pamidronate-treatment should not be stopped once started." | 5.11 | Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer. ( Balafouta, M; Gennatas, C; Kokakis, J; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Pistevou-Gombaki, K; Varela, MN; Vlahos, LJ, 2004) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 5.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "The study was a 1-yr randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer." | 5.11 | Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. ( Chehal, A; Fuleihan, Gel-H; Mahfoud, Z; Mourad, YA; Salamoun, M; Salem, Z; Shamseddine, A, 2005) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 5.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Results of a large, randomized, comparative phase III trial involving 1,130 breast cancer patients demonstrated that 4 mg zoledronic acid and 90 mg pamidronate were equally effective at reducing the occurrence and delaying the onset of skeletal-related events in patients with bone metastases secondary to breast cancer." | 5.10 | Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. ( Coleman, RE, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 5.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 5.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "Bisphosphonates are now the standard treatment for tumor-induced hypercalcemia (TIH), and pamidronate can normalize serum Ca in at least 90% of the patients treated for the first time." | 5.09 | Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. ( Body, JJ; Dumon, JC; Louviaux, I, 2000) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 5.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 5.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "The effect of pamidronate treatment on the first development of bone metastases was investigated in 124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal metastases (n = 91), but no bone metastases in a randomised, multicentre, open controlled study." | 5.08 | Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? ( Beex, LV; Blijham, G; Cleton, FJ; Hermans, J; Papapoulos, SE; Sleeboom, HP; van Eck-Smit, BC; van Holten-Verzantvoort, AT, 1996) |
| "Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients)." | 5.08 | Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. ( Bonneterre, J; Calabresi, F; Campos, D; Conte, PF; Ford, JM; Francini, G; Latreille, J; Mauriac, L; Santos, R, 1996) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 5.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| " Anderson, the use of the recently approved bisphosphonate pamidronate (Aredia) became a part of the standard of care pathway for the treatment of osteolytic metastases from breast cancer." | 5.08 | Fitting new modalities into practice guidelines. ( Theriault, RL, 1997) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 5.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 5.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 5.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "Four intravenous regimens of pamidronate (Aredia) were evaluated for palliative treatment of bone metastases in 2 randomized open-label trials in patients with breast cancer (n = 61) or prostate cancer (n = 58)." | 5.07 | Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. ( Glover, D; Grabelsky, S; Harvey, H; Lipton, A; Macerata, R; Seaman, J; Zelenakas, K, 1994) |
| "An open, randomized study was performed to assess the effects of supportive pamidronate treatment on morbidity from bone metastases in breast cancer patients." | 5.07 | Palliative pamidronate treatment in patients with bone metastases from breast cancer. ( Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 5.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 5.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormonetherapy." | 5.07 | Disodium pamidronate in the treatment of bone metastases from breast cancer. ( Bajetta, E; Bochicchio, AM; Colleoni, M; Nolè, F, 1993) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 5.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "Zoledronic acid seems to be the most efficacious bisphosphonate for reducing the risk of SREs in patients with cancer of the breast or prostate and those with multiple myeloma." | 4.89 | Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. ( Brown, J; Fullarton, JR; Palmieri, C, 2013) |
| ", oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM." | 4.87 | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. ( Berenson, J; Dimopoulos, MA; Terpos, E, 2011) |
| "For more than 10 years, based on the results with the bisphosphonate clodronic acid, it has been discussed, whether the occurrence of breast cancer metastases can be avoided or at least delayed by administration of bisphosphonates." | 4.86 | [Bisphosphonates in adjuvant therapy of breast cancer]. ( Deuber, HJ; Theiss, F, 2010) |
| " Indeed, clinical data suggest that in addition to being well-tolerated and efficacious in maintaining bone health, BPs including clodronate, pamidronate, and zoledronic acid also improve cancer-related outcomes such as tumor response, disease-free survival, and overall survival in patients with breast cancer." | 4.86 | Bisphosphonates as anticancer therapy for early breast cancer. ( Jahanzeb, M; Mahtani, R, 2010) |
| "The American Society of Clinical Oncology recommends bisphosphonate use, such as intravenous pamidronate, for women with breast cancer who have radiographic evidence of bone destruction." | 4.85 | Pamidronate-induced kidney injury in a patient with metastatic breast cancer. ( Nagahama, M; Sica, DA, 2009) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| " As regards pamidronate, several open, controlled studies have shown a significant effect on bone pain in 30-70% of breast cancer patients." | 4.79 | Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. ( Strang, P, 1996) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| "Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended." | 3.77 | American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. ( Barlow, WE; Biermann, JS; Bosserman, LD; Geoghegan, C; Hillner, BE; Janjan, NA; Temin, S; Theriault, RL; Van Poznak, CH; Von Roenn, JH; Yee, GC; Zuckerman, DS, 2011) |
| " Osteonecrosis of the jaw is an uncommon but serious event in patients receiving monthly intravenous bisphosphonates or denosumab." | 3.76 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. ( Aapro, M; Costa, L; Saad, F, 2010) |
| "We investigated the effect on hTERT gene expression of clodronate, alendronate, and pamidronate (from 10(-6) M to 10(-5) M) on MCF-7 and T47D human breast cancer cells, using real time RTPCR." | 3.74 | Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. ( Azzarello, G; Balducci, E; Bertoldo, F; Dalle Carbonare, L; Fracalossi, A; Lo Cascio, V; Valenti, MT; Vinante, O, 2007) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 3.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 3.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 3.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "To estimate the costs and consequences of using pamidronate compared to zoledronic acid in the prophylactic management of skeletal morbidity among breast cancer patients in the UK." | 3.73 | Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. ( Clegg, JP; Davie, AM; Guest, JF; McCloskey, E, 2005) |
| " We studied the direct effects of clodronate, alendronate, and pamidronate (from 10(-6) to 10(-4) M) on MCF-7 human breast cancer cell line." | 3.73 | Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. ( Azzarello, G; Balducci, E; Crepaldi, G; Dalle Carbonare, L; Giannini, S; Realdi, G; Valenti, MT; Vinante, O, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 3.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "The aim of this study was to compare the cost-effectiveness of oral ibandronate with zoledronic acid and generic pamidronate (both administered by IV) for the treatment of bone metastases in patients with breast cancer receiving oral hormonal therapy in the United Kingdom." | 3.73 | Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| "The Japanese Ministry of Health, Labor and Welfare approved the use of pamidronate in November 2004 at a dose of 90 mg/day/month especially for Japanese breast cancer patients with lytic bone metastasis." | 3.73 | [Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis]. ( Aogi, K; Ohsumi, S; Okita, A; Taira, N; Takashima, S, 2006) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 3.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "Charts and electronic files of breast cancer patients with bone metastases who had received either clodronate or pamidronate at any time between January 2000 and December 2001 at our center were retrospectively reviewed." | 3.72 | Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. ( Chow, E; Clemons, M; Enright, K, 2004) |
| "Pamidronate has been mainly associated with collapsing focal segmental glomerulosclerosis." | 3.72 | Podocyte injury associated glomerulopathies induced by pamidronate. ( Abulezz, SR; Barri, YM; Bonsib, SM; Munshi, NC; Sukumalchantra, S; Walker, PD; Wallach, J, 2004) |
| "To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase." | 3.72 | Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004) |
| "The most serious, potentially life-threatening manifestation of 'flare' is hypercalcemia, registered in 4-5% of breast cancer patients with bone metastases, usually during the first few weeks of tamoxifen treatment." | 3.71 | Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates? ( Jelic, S; Mitrović, L; Nikolic-Tomasević, Z; Popov, I; Radosavljević, D, 2001) |
| "Our goal was to evaluate the impact of pamidronate therapy on medical resource utilization for treatment of bone metastases among patients with breast cancer." | 3.71 | The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. ( Ackerman, SJ; Beusterien, KM; Hill, MC; Zacker, C, 2001) |
| " Thirty-seven patients with newly diagnosed bone metastases from breast cancer, randomized to receive oral pamidronate or placebo tablets in addition to anticancer treatment within the context of a multicentre EORTC trial, who were both assessable for radiographic response in bone and had serum and urine samples collected for more than 1 month were studied." | 3.70 | Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. ( Bastit, P; Coleman, R; Ford, J; Lacombe, D; Leonard, R; Michel, J; Mignolet, F; Nortier, J; Rose, C; Tubiana-Hulin, M; Vinholes, J; Wildiers, J, 1999) |
| "Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions." | 3.70 | Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. ( Desch, CE; Hillner, BE; Smith, TJ; Weeks, JC, 2000) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 3.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| " Pamidronate (Aredia(TM)) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases." | 3.70 | Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). ( Coleman, RE, 2000) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| " We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate." | 3.69 | Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. ( Body, JJ; Delmas, PD; Dumon, JC; Gineyts, E, 1997) |
| " We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients)." | 3.68 | [Disodium pamidronate (APD) in the treatment of bone metastases]. ( Costa, L; da Costa, EB; Moreira, C, 1993) |
| " The urinary excretion of these compounds, expressed as a ratio to urinary creatinine, has been measured using ion-pair reversed phase high-performance liquid chromatography in 20 patients receiving oral pamidronate for bone metastases from breast cancer." | 3.68 | Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. ( Coleman, RE; Ford, J; Houston, S; James, I; Leonard, RC; Rodger, A; Rubens, RD, 1992) |
| "The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally." | 3.68 | The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. ( Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 3.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "The bisphosphonate pamidronate (3 amino-1, 1-hydroxypropylidene bisphosphonate (APD), Ciba-Geigy) is a powerful inhibitor of osteoclast function and has been shown to significantly reduce osteolysis associated with bone metastases in breast cancer." | 3.68 | Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. ( Dodwell, DJ; Ford, J; Howell, A, 1990) |
| "Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval." | 2.78 | Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. ( Amir, E; Carlsson, L; Clemons, M; Dranitsaris, G; Freedman, O; Laupacis, A; Tannock, IF; Tomlinson, G, 2013) |
| "dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days." | 2.72 | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. ( Bekker, PJ; Body, JJ; Coleman, RE; Facon, T; Fan, M; Geurs, F; Holloway, D; Lipton, A; Peterson, MC, 2006) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 2.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease." | 2.70 | Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. ( Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ, 2001) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 2.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "Pamidronate is a potent biphosphonate which modulates tumour-induced osteolysis (TIO) by inhibiting osteoclast-mediated bone resorption." | 2.68 | Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. ( Bruning, PF; Ford, JM; Mauriac, L; May-Levin, F; Rose, C; Soukop, M; Tyrrell, CT, 1995) |
| "We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion." | 2.68 | Metabolic effects of pamidronate in patients with metastatic bone disease. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1996) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "In view of previous animal studies showing that pamidronate (Aredia) can cause renal damage, and human data indicating that pamidronate in doses of 60-90 mg is more effective in the control of tumor-induced hypercalcemia than when given at lower doses, we decided to investigate whether pamidronate 90 mg infused over 60 minutes at weekly intervals had any adverse effects on renal function in patients with bone metastases." | 2.67 | Intravenous pamidronate: infusion rate and safety. ( Coleman, T; Collinson, M; Ford, JM; Madsen, EL; Tyrrell, CJ, 1994) |
| "There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented." | 2.66 | Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987) |
| "In metastatic breast cancer the most common metastatic site is bone." | 2.47 | [Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer]. ( Taguchi, T, 2011) |
| "Zoledronic acid has also demonstrated significant long-term benefits in randomized trials in prostate cancer and other solid tumors, whereas other bisphosphonates have failed." | 2.43 | Management of bone metastases in breast cancer. ( Lipton, A, 2005) |
| "Zoledronic acid has also been compared with another active bisphosphonate (i." | 2.43 | Bisphosphonates in breast cancer. ( Coleman, RE, 2005) |
| " The safety profiles among all intravenous bisphosphonates were similar; patients treated with intravenous bisphosphonates reported notably less bone pain but a higher incidence of mild to moderate transient infusion-related adverse events (eg, nausea, vomiting, myalgia, and anorexia) compared with placebo." | 2.43 | Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. ( Gordon, DH, 2005) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 2.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Patients with breast cancer associated solely with osseous metastasis may survive for a number of years." | 2.41 | [Therapeutic value of aredia in treatment of breast carcinoma]. ( Diel, IJ, 2000) |
| "Patients with breast cancer associated solely with osseous metastasis may live for a number of years." | 2.41 | Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000) |
| "Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity." | 2.40 | Bisphosphonates and breast carcinoma. ( Lipton, A, 1997) |
| "Experts in the field were approached." | 2.40 | Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 2.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood." | 2.39 | Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996) |
| "Human breast cancer is among one major health concerns with high prevalence and mortality among women worldwide." | 1.91 | Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics. ( Ahmed, A; Hashim, Z; Ilyas, A; Syed, B; Syed, N; Zarina, S, 2023) |
| " In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis." | 1.56 | Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. ( Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H, 2020) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 1.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| " This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain." | 1.46 | Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. ( Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC, 2017) |
| "The medical records of 534 women with breast cancer who developed bone metastases between 1999 and 2011 were reviewed." | 1.43 | Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. ( Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M, 2016) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "Human breast cancer is a major cause of global morbidity and mortality in women and it is a process that involves numerous molecular and cellular alterations attributed to environmental substances and agents such as hormones." | 1.42 | Antitumor activity of pamidronate in breast cancer cells transformed by low doses of α-particles and estrogen in vitro. ( Calaf, GM; Ponce-Cusi, R, 2015) |
| "Nineteen patients were diagnosed with breast cancer and 18 with prostate cancer." | 1.40 | Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. ( Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F, 2014) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%)." | 1.36 | Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. ( Clemons, M; Dranatisaris, G; Myers, J; Simmons, C; Trinkaus, M, 2010) |
| "The patient had a medical history of breast cancer with bone metastasis that was treated by chemotherapy with 45 mg pamidronate in 2 weekly courses for 16 months." | 1.36 | [A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate]. ( Inokuchi, S; Koga, C; Koga, M; Kusukawa, J; Tanaka, Y; Yokomizo, Y, 2010) |
| "MCF-7 breast cancer cells were chosen as aminobisphosphonates are employed to alleviate bone resorption in this malignancy." | 1.36 | Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells. ( Chiplunkar, SV; Dhar, S, 2010) |
| "In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up." | 1.35 | Use of intravenous bisphosphonates in older women with breast cancer. ( Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF, 2008) |
| "However, for women, metastatic breast cancer still remains the number one cause of cancer death in Europe, and the detection and treatment of micrometastatic disease represent the most important challenge in breast cancer management." | 1.35 | Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? ( Coleman, RE, 2009) |
| "Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables." | 1.35 | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009) |
| "Recent cases of bone necrosis of the jaws have been associated with the use of bisphosphonate therapy." | 1.35 | Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management. ( Fayans, EP; Grewal, VS, 2008) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "The frequency of bone metastases of breast cancer has been reported to be 65-75% of all breast cancer patients, and, in autopsy example at Shikoku Cancer Center, metastasis was recognized to be 74." | 1.33 | [The incidence and management of bone metastasis from breast cancer]. ( Fujiuchi, N; Ookubo, K; Saeki, T; Takeuchi, H, 2006) |
| "The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient." | 1.33 | Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006) |
| "Breast cancer is the first cause of this dissemination." | 1.32 | [Uterine and ovarian metastases 28 years after the discovery of breast cancer]. ( Chabert, P; Dieny, A; Grimonpont, A; Hadjseyd, M; Mechin-Cretinon, I; Mohseni, H; Truong, P, 2003) |
| "In women with advanced breast cancer and bone metastases, bisphosphonates reduce the incidence of hypercalcaemia and skeletal morbidity." | 1.31 | Bisphosphonates induce apoptosis in human breast cancer cell lines. ( Arnett, TR; Colston, KW; Mansi, JL; Pirianov, G; Senaratne, SG, 2000) |
| "We investigated their effects on breast cancer cells using three human cell lines, namely, MCF-7, T47D, and MDA." | 1.31 | Bisphosphonates induce breast cancer cell death in vitro. ( Body, JJ; Fromigue, O; Lagneaux, L, 2000) |
| "Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases." | 1.31 | Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. ( Appel, GB; D'Agati, VD; Dratch, AD; Fenves, AZ; Fine, PL; Jagannath, S; Kuhn, JA; Loon, NR; Markowitz, GS, 2001) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 1.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 1.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "This increased bone resorption is inhibited by pamidronate without reducing G-CSF-induced HPC mobilization, suggesting that the activation of bone resorption after G-CSF administration is not the direct cause of HPC mobilization as initially hypothesized, but a parallel event." | 1.30 | Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. ( Lévesque, JP; Moore, RJ; Morris, HA; Simmons, PJ; Takamatsu, Y; To, LB, 1998) |
| "Malignant hypercalcemia is caused by both increased bone resorption and enhanced tubular reabsorption of calcium." | 1.28 | Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. ( Burckhardt, P; Jaeger, P; Thiebaud, D, 1990) |
| "No other systemic therapy for breast cancer was prescribed." | 1.27 | Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). ( Coleman, RE; Miles, M; Rubens, RD; Scrivener, W; Woll, PJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (5.06) | 18.7374 |
| 1990's | 77 (32.49) | 18.2507 |
| 2000's | 111 (46.84) | 29.6817 |
| 2010's | 35 (14.77) | 24.3611 |
| 2020's | 2 (0.84) | 2.80 |
| Authors | Studies |
|---|---|
| Syed, N | 1 |
| Ilyas, A | 1 |
| Syed, B | 1 |
| Ahmed, A | 1 |
| Zarina, S | 1 |
| Hashim, Z | 1 |
| Tanaka, H | 1 |
| Makita, C | 1 |
| Manabe, Y | 1 |
| Kajima, M | 1 |
| Matsuyama, K | 1 |
| Matsuo, M | 1 |
| Van Poznak, C | 2 |
| Somerfield, MR | 2 |
| Moy, B | 2 |
| Barlow, WE | 2 |
| Biermann, JS | 2 |
| Bosserman, LD | 2 |
| Clemons, MJ | 2 |
| Dhesy-Thind, SK | 1 |
| Dillmon, MS | 1 |
| Eisen, A | 1 |
| Frank, ES | 1 |
| Jagsi, R | 1 |
| Jimenez, R | 1 |
| Theriault, RL | 8 |
| Vandenberg, TA | 1 |
| Yee, GC | 2 |
| Mahmoud, S | 1 |
| Mitwally, H | 1 |
| El Zeer, HS | 1 |
| El Madhoun, I | 1 |
| Khatib, M | 1 |
| Ben-Aharon, I | 1 |
| Vidal, L | 1 |
| Rizel, S | 1 |
| Yerushalmi, R | 1 |
| Shpilberg, O | 1 |
| Sulkes, A | 1 |
| Stemmer, SM | 1 |
| Palmieri, C | 1 |
| Fullarton, JR | 1 |
| Brown, J | 1 |
| Mansouri, M | 1 |
| Mirzaei, SA | 1 |
| Lage, H | 1 |
| Mousavi, SS | 1 |
| Elahian, F | 1 |
| Oster, G | 1 |
| Lamerato, L | 1 |
| Glass, AG | 1 |
| Richert-Boe, KE | 1 |
| Lopez, A | 1 |
| Chung, K | 1 |
| Richhariya, A | 1 |
| Dodge, T | 1 |
| Wolff, GG | 1 |
| Balakumaran, A | 1 |
| Edelsberg, J | 1 |
| Addison, CL | 1 |
| Bouganim, N | 2 |
| Hilton, J | 1 |
| Vandermeer, L | 2 |
| Dent, S | 2 |
| Amir, E | 2 |
| Hopkins, S | 1 |
| Kuchuk, I | 2 |
| Segal, R | 1 |
| Song, X | 2 |
| Gertler, S | 2 |
| Mazzarello, S | 2 |
| Dranitsaris, G | 6 |
| Ooi, D | 1 |
| Pond, G | 1 |
| Clemons, M | 7 |
| Xie, F | 1 |
| Hopkins, RB | 1 |
| Burke, N | 1 |
| Habib, M | 1 |
| Angelis, CD | 1 |
| Pasetka, M | 1 |
| Giotis, A | 1 |
| Goeree, R | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Ponce-Cusi, R | 1 |
| Calaf, GM | 1 |
| Jacobs, C | 1 |
| Smith, S | 1 |
| Verma, S | 3 |
| Simos, S | 1 |
| Cella, D | 1 |
| Rayson, D | 1 |
| Tanaka, R | 1 |
| Yonemori, K | 1 |
| Hirakawa, A | 1 |
| Kinoshita, F | 1 |
| Takahashi, N | 1 |
| Hashimoto, J | 1 |
| Kodaira, M | 1 |
| Yamamoto, H | 1 |
| Yunokawa, M | 1 |
| Shimizu, C | 1 |
| Fujimoto, M | 1 |
| Fujiwara, Y | 1 |
| Tamura, K | 1 |
| Giordano, SH | 1 |
| Fang, S | 1 |
| Duan, Z | 1 |
| Kuo, YF | 1 |
| Hortobagyi, GN | 6 |
| Goodwin, JS | 1 |
| Aarabi, S | 1 |
| Draper, L | 1 |
| Grayson, B | 1 |
| Gurtner, GC | 1 |
| Dong, M | 1 |
| Feng, FY | 1 |
| Zhang, Y | 1 |
| Xie, GR | 1 |
| Wang, YJ | 1 |
| Liu, JW | 1 |
| Song, ST | 1 |
| Zhou, QH | 1 |
| Ren, J | 2 |
| Jiao, SC | 1 |
| Li, J | 1 |
| Wang, XW | 1 |
| Chen, Q | 1 |
| Wang, ZH | 1 |
| Xu, N | 1 |
| Feng, JF | 1 |
| Young, P | 1 |
| Finn, BC | 1 |
| Bruetman, JE | 1 |
| Trinkaus, M | 1 |
| Simmons, C | 1 |
| Myers, J | 1 |
| Dranatisaris, G | 1 |
| Coleman, RE | 22 |
| Nagahama, M | 1 |
| Sica, DA | 1 |
| Major, PP | 3 |
| Cook, RJ | 4 |
| Lipton, A | 23 |
| Smith, MR | 2 |
| Terpos, E | 3 |
| Vahtsevanos, K | 1 |
| Kyrgidis, A | 1 |
| Verrou, E | 1 |
| Katodritou, E | 1 |
| Triaridis, S | 1 |
| Andreadis, CG | 1 |
| Boukovinas, I | 1 |
| Koloutsos, GE | 1 |
| Teleioudis, Z | 1 |
| Kitikidou, K | 1 |
| Paraskevopoulos, P | 1 |
| Zervas, K | 1 |
| Antoniades, K | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Otto, S | 1 |
| Schuler, K | 1 |
| Ihrler, S | 1 |
| Ehrenfeld, M | 1 |
| Mast, G | 1 |
| Tanaka, Y | 1 |
| Koga, M | 1 |
| Yokomizo, Y | 1 |
| Inokuchi, S | 1 |
| Koga, C | 1 |
| Kusukawa, J | 1 |
| Heras, P | 1 |
| Hatzopoulos, A | 1 |
| Heras, V | 1 |
| Kritikos, N | 1 |
| Karagiannis, S | 1 |
| Kritikos, K | 1 |
| Hussein, O | 1 |
| Tiedemann, K | 1 |
| Komarova, SV | 1 |
| Deuber, HJ | 1 |
| Theiss, F | 1 |
| Mahtani, R | 1 |
| Jahanzeb, M | 1 |
| Aapro, M | 1 |
| Saad, F | 2 |
| Costa, L | 3 |
| Dhar, S | 1 |
| Chiplunkar, SV | 1 |
| Van Poznak, CH | 1 |
| Temin, S | 1 |
| Janjan, NA | 1 |
| Geoghegan, C | 1 |
| Hillner, BE | 2 |
| Zuckerman, DS | 1 |
| Von Roenn, JH | 1 |
| Dimopoulos, MA | 2 |
| Berenson, J | 2 |
| Taguchi, T | 1 |
| Yoshizawa, H | 1 |
| Akimoto, T | 1 |
| Nishino, K | 1 |
| Inoue, M | 1 |
| Ito, C | 1 |
| Takeda, S | 1 |
| Kotoda, A | 1 |
| Tamba, K | 1 |
| Yumura, W | 1 |
| Muto, S | 1 |
| Ueda, Y | 1 |
| Kusano, E | 1 |
| Ngamphaiboon, N | 1 |
| Frustino, JL | 1 |
| Kossoff, EB | 1 |
| Sullivan, MA | 1 |
| O'Connor, TL | 1 |
| Berenson, JR | 2 |
| Niikura, N | 1 |
| Liu, J | 1 |
| Hayashi, N | 1 |
| Palla, SL | 1 |
| Tokuda, Y | 1 |
| Ueno, NT | 1 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Freedman, O | 1 |
| Carlsson, L | 1 |
| Tomlinson, G | 1 |
| Laupacis, A | 1 |
| Tannock, IF | 1 |
| Brown, JE | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Nagykálnai, T | 1 |
| Landherr, L | 1 |
| Zatkóné, GP | 1 |
| Gyuricska, A | 1 |
| Small, E | 1 |
| Gleason, D | 1 |
| Gordon, D | 2 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 1 |
| Reitsma, D | 1 |
| Seaman, J | 5 |
| Body, JJ | 13 |
| Greipp, P | 1 |
| Facon, T | 2 |
| Geurs, F | 2 |
| Fermand, JP | 1 |
| Harousseau, JL | 1 |
| Mariette, X | 1 |
| Williams, CD | 1 |
| Nakanishi, A | 1 |
| Holloway, D | 2 |
| Martin, SW | 1 |
| Dunstan, CR | 1 |
| Bekker, PJ | 2 |
| Cook, R | 1 |
| Mohseni, H | 1 |
| Truong, P | 1 |
| Hadjseyd, M | 1 |
| Grimonpont, A | 1 |
| Dieny, A | 1 |
| Mechin-Cretinon, I | 1 |
| Chabert, P | 1 |
| Haritoglou, C | 1 |
| Mueller, AJ | 1 |
| Kouloulias, V | 1 |
| Matsopoulos, G | 1 |
| Kouvaris, J | 1 |
| Dardoufas, C | 1 |
| Bottomley, A | 1 |
| Varela, M | 1 |
| Uzunoglu, N | 1 |
| Antypas, C | 1 |
| Metafa, A | 1 |
| Moulopoulos, A | 1 |
| Sandilos, P | 1 |
| Vlahos, L | 1 |
| Rosen, LS | 3 |
| Kaminski, M | 2 |
| Howell, A | 6 |
| Belch, A | 1 |
| Mackey, J | 1 |
| Apffelstaedt, J | 1 |
| Hussein, MA | 1 |
| Reitsma, DJ | 4 |
| Chen, BL | 2 |
| Seaman, JJ | 6 |
| Enright, K | 1 |
| Chow, E | 1 |
| Gordon, DH | 2 |
| Dugan, W | 1 |
| Major, P | 2 |
| Eisenberg, PD | 1 |
| Provencher, L | 1 |
| Simeone, J | 3 |
| Barri, YM | 1 |
| Munshi, NC | 1 |
| Sukumalchantra, S | 1 |
| Abulezz, SR | 1 |
| Bonsib, SM | 1 |
| Wallach, J | 1 |
| Walker, PD | 1 |
| Weinfurt, KP | 1 |
| Castel, LD | 1 |
| Li, Y | 1 |
| Timbie, JW | 1 |
| Glendenning, GA | 2 |
| Schulman, KA | 2 |
| Chen, BE | 1 |
| Wenzel, C | 1 |
| Bartsch, R | 1 |
| Hussian, D | 1 |
| Pluschnig, U | 1 |
| Locker, GJ | 1 |
| Sevelda, U | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Montemurro, F | 1 |
| Russo, F | 1 |
| Martincich, L | 1 |
| Cirillo, S | 1 |
| Gatti, M | 1 |
| Aglietta, M | 1 |
| Regge, D | 1 |
| Rai, Y | 1 |
| Sagara, Y | 2 |
| Takahama, T | 1 |
| Ando, M | 1 |
| Kouloulias, VE | 2 |
| Kouvaris, JR | 2 |
| Mystakidou, K | 1 |
| Varela, MN | 1 |
| Kokakis, J | 1 |
| Pistevou-Gombaki, K | 1 |
| Balafouta, M | 1 |
| Gennatas, C | 1 |
| Vlahos, LJ | 2 |
| Romanus, D | 1 |
| Iscoe, N | 1 |
| Deangelis, C | 1 |
| Shear, N | 1 |
| Einarson, TR | 1 |
| Zhang, PL | 1 |
| Lun, M | 1 |
| Siegelmann-Danieli, N | 1 |
| Blasick, TM | 1 |
| Brown, RE | 1 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Wada, N | 1 |
| Ishii, S | 1 |
| Ikeda, T | 1 |
| Kitajima, M | 1 |
| Wang, DJ | 1 |
| Liu, HQ | 1 |
| Chen, YL | 1 |
| Zhan, QY | 1 |
| Cai, Y | 1 |
| Liu, MZ | 1 |
| Reed, SD | 1 |
| Radeva, JI | 1 |
| Harvey, HA | 2 |
| Fuleihan, Gel-H | 1 |
| Salamoun, M | 1 |
| Mourad, YA | 1 |
| Chehal, A | 1 |
| Salem, Z | 1 |
| Mahfoud, Z | 1 |
| Shamseddine, A | 1 |
| Gralow, J | 1 |
| De Cock, E | 2 |
| Hutton, J | 2 |
| Canney, P | 2 |
| Barrett-Lee, P | 3 |
| Neary, MP | 2 |
| Lewis, G | 2 |
| Liang, JG | 1 |
| Jiang, NY | 1 |
| DU, JQ | 1 |
| Lu, XP | 1 |
| Liu, XG | 1 |
| Chen, SX | 1 |
| Guest, JF | 1 |
| Clegg, JP | 1 |
| Davie, AM | 1 |
| McCloskey, E | 2 |
| Dalle Carbonare, L | 2 |
| Valenti, MT | 2 |
| Azzarello, G | 2 |
| Balducci, E | 2 |
| Crepaldi, G | 1 |
| Realdi, G | 1 |
| Vinante, O | 2 |
| Giannini, S | 1 |
| Durie, BG | 1 |
| Katz, M | 1 |
| Crowley, J | 1 |
| Liauw, W | 1 |
| Segelov, E | 1 |
| Lih, A | 1 |
| Dunleavy, R | 1 |
| Links, M | 1 |
| Ward, R | 1 |
| Cremers, SC | 1 |
| Papapoulos, SE | 4 |
| Gelderblom, H | 1 |
| Seynaeve, C | 1 |
| den Hartigh, J | 1 |
| Vermeij, P | 1 |
| van der Rijt, CC | 1 |
| van Zuylen, L | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Pastor-Zuazaga, D | 1 |
| Garatea-Crelgo, J | 1 |
| Martino-Gorbea, R | 1 |
| Etayo-Pérez, A | 1 |
| Sebastián-López, C | 1 |
| Fan, M | 1 |
| Peterson, MC | 1 |
| Verdijk, R | 1 |
| Franke, HR | 1 |
| Wolbers, F | 1 |
| Vermes, I | 1 |
| Sauter, M | 1 |
| Jülg, B | 1 |
| Porubsky, S | 1 |
| Cohen, C | 1 |
| Fischereder, M | 1 |
| Sitter, T | 1 |
| Schlondorff, D | 1 |
| Gröne, HJ | 1 |
| Diaz-Borjon, A | 1 |
| Seyler, TM | 1 |
| Chen, NL | 1 |
| Lim, SS | 1 |
| Saeki, T | 1 |
| Ookubo, K | 1 |
| Takeuchi, H | 1 |
| Fujiuchi, N | 1 |
| Wutzl, A | 1 |
| Eisenmenger, G | 1 |
| Hoffmann, M | 1 |
| Czerny, C | 1 |
| Moser, D | 1 |
| Pietschmann, P | 1 |
| Ewers, R | 1 |
| Baumann, A | 1 |
| Aogi, K | 1 |
| Okita, A | 1 |
| Taira, N | 1 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Ooi, WS | 1 |
| Yogendran, G | 1 |
| Sukovic, T | 1 |
| Wong, BY | 1 |
| Pritchard, KI | 1 |
| Trudeau, M | 1 |
| Cole, DE | 2 |
| Culbert, EC | 1 |
| Schfirin, BS | 1 |
| de Lemos, ML | 1 |
| Taylor, SC | 1 |
| Barnett, JB | 1 |
| Hu, F | 1 |
| Levin, A | 1 |
| Moravan, V | 1 |
| O'Reilly, SE | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Bertoldo, F | 1 |
| Fracalossi, A | 1 |
| Lo Cascio, V | 1 |
| Ooi, W | 1 |
| Bloomfield, D | 1 |
| Dougherty, L | 1 |
| Harries, M | 1 |
| Laing, R | 1 |
| Patel, H | 1 |
| Walker, M | 1 |
| Sanna, G | 1 |
| Preda, L | 1 |
| Bruschini, R | 1 |
| Cossu Rocca, M | 1 |
| Verri, E | 1 |
| Bellomi, M | 1 |
| Goldhirsch, A | 1 |
| Nole, F | 2 |
| Engroff, SL | 1 |
| Kim, DD | 1 |
| Yamada, K | 4 |
| Kohno, N | 3 |
| Bedogni, A | 1 |
| Blandamura, S | 1 |
| Lokmic, Z | 1 |
| Palumbo, C | 1 |
| Ragazzo, M | 1 |
| Ferrari, F | 1 |
| Tregnaghi, A | 1 |
| Pietrogrande, F | 1 |
| Procopio, O | 1 |
| Saia, G | 1 |
| Ferretti, M | 1 |
| Bedogni, G | 1 |
| Chiarini, L | 1 |
| Ferronato, G | 1 |
| Ninfo, V | 1 |
| Lo Russo, L | 1 |
| Lo Muzio, L | 1 |
| Nocini, PF | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Schivazappa, C | 1 |
| Berto, P | 1 |
| Baldini, E | 1 |
| Barni, S | 1 |
| Dauria, G | 1 |
| Cortesi, E | 1 |
| Grewal, VS | 1 |
| Fayans, EP | 1 |
| Kristensen, B | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 1 |
| Jensen, MB | 1 |
| Andersen, J | 1 |
| Bjerregaard, B | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| Kamby, C | 1 |
| Lindman, H | 1 |
| Nordenskjöld, B | 1 |
| Bergh, J | 1 |
| Glover, D | 2 |
| Keller, A | 1 |
| Miller, AA | 1 |
| Browning, S | 1 |
| Fram, RJ | 1 |
| George, S | 1 |
| Zelenakas, K | 3 |
| Macerata, RS | 1 |
| Harvey, H | 2 |
| Grabelsky, S | 1 |
| Macerata, R | 1 |
| Tyrrell, CJ | 2 |
| Thürlimann, B | 2 |
| van Holten-Verzantvoort, AT | 5 |
| Kroon, HM | 2 |
| Bijvoet, OL | 4 |
| Cleton, FJ | 4 |
| Beex, LV | 4 |
| Blijham, G | 2 |
| Hermans, J | 4 |
| Neijt, JP | 2 |
| Sleeboom, HP | 2 |
| Collinson, M | 1 |
| Madsen, EL | 1 |
| Ford, JM | 4 |
| Coleman, T | 1 |
| Conte, PF | 2 |
| Giannessi, PG | 1 |
| Latreille, J | 2 |
| Mauriac, L | 3 |
| Koliren, L | 1 |
| Calabresi, F | 2 |
| Evans, CE | 1 |
| Braidman, IP | 1 |
| Gucalp, R | 1 |
| Theriault, R | 2 |
| Gill, I | 1 |
| Madajewicz, S | 1 |
| Chapman, R | 1 |
| Navari, R | 1 |
| Ahmann, F | 1 |
| Heffernan, M | 4 |
| Knight, RD | 5 |
| Colleoni, M | 1 |
| Bochicchio, AM | 1 |
| Bajetta, E | 1 |
| Morant, R | 1 |
| Jungi, WF | 1 |
| Radziwill, A | 1 |
| Lichinitser, MR | 1 |
| Vyshinskaia, GV | 1 |
| Kupchan, DZ | 1 |
| Liubimova, NV | 1 |
| Grutters, JC | 1 |
| Hermus, AR | 1 |
| de Mulder, PH | 1 |
| Moreira, C | 1 |
| da Costa, EB | 1 |
| Tyrrell, CT | 1 |
| Bruning, PF | 1 |
| May-Levin, F | 1 |
| Rose, C | 2 |
| Soukop, M | 1 |
| Nesković-Konstantinović, Z | 1 |
| Mitrović, L | 2 |
| Petrović, J | 1 |
| Stamatović, L | 1 |
| Ristović, Z | 1 |
| Kanis, JA | 4 |
| Dumon, JC | 3 |
| Piccart, M | 2 |
| Ford, J | 5 |
| Vinholes, J | 2 |
| Guo, CY | 1 |
| Purohit, OP | 3 |
| Eastell, R | 1 |
| van Eck-Smit, BC | 1 |
| Santos, R | 1 |
| Campos, D | 1 |
| Bonneterre, J | 1 |
| Francini, G | 1 |
| Paterson, AH | 2 |
| Powles, TJ | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Illidge, TM | 1 |
| Hussey, M | 1 |
| Godden, CW | 1 |
| Delmas, PD | 4 |
| Possinger, K | 1 |
| Flath, B | 1 |
| Akrivakis, K | 1 |
| Porter, L | 3 |
| Blayney, D | 2 |
| Sinoff, C | 2 |
| Wheeler, H | 2 |
| Simeone, JF | 2 |
| Bankhead, C | 1 |
| Siris, ES | 1 |
| Gineyts, E | 1 |
| Strang, P | 1 |
| Hultborn, R | 1 |
| Gundersen, S | 1 |
| Rydén, S | 1 |
| Holmberg, E | 1 |
| Carstensen, J | 1 |
| Wallgren, UB | 1 |
| Kilany, S | 1 |
| Blomqvist, C | 1 |
| Elomaa, I | 1 |
| Oura, S | 1 |
| Sakurai, T | 2 |
| Yoshimura, G | 2 |
| Tamaki, T | 2 |
| Umemura, T | 2 |
| Kokawa, Y | 1 |
| Kao, G | 1 |
| Rubiales, AS | 1 |
| Centeno, C | 1 |
| Boissier, S | 1 |
| Magnetto, S | 1 |
| Frappart, L | 1 |
| Cuzin, B | 1 |
| Ebetino, FH | 1 |
| Clezardin, P | 1 |
| Vinholes, JJ | 1 |
| Zekri, J | 1 |
| Kage, K | 1 |
| Nagahama, T | 1 |
| Sekine, I | 1 |
| Maruyama, M | 1 |
| Ogata, E | 1 |
| Bloomfield, DJ | 1 |
| Mellars, K | 3 |
| Cömlekçi, A | 1 |
| Biberoglu, S | 1 |
| Hekimsoy, Z | 1 |
| Okan, I | 1 |
| Pişkin, O | 1 |
| Sekeroglu, B | 1 |
| Alakavuklar, M | 1 |
| Kokufu, I | 3 |
| Kim, YH | 3 |
| Peng, YF | 1 |
| Fukuda, K | 3 |
| Yamamoto, M | 3 |
| Yano, T | 3 |
| Kitano, H | 3 |
| Ripamonti, C | 1 |
| Fulfaro, F | 1 |
| Polastri, D | 1 |
| De Conno, F | 1 |
| Laffranchi, A | 1 |
| Moliterni, A | 1 |
| Adamietz, IA | 1 |
| Takamatsu, Y | 1 |
| Simmons, PJ | 1 |
| Moore, RJ | 1 |
| Morris, HA | 1 |
| To, LB | 1 |
| Lévesque, JP | 1 |
| Houston, S | 2 |
| Rubens, RD | 6 |
| Kandra, A | 1 |
| Phillips, E | 1 |
| Knowles, S | 1 |
| Weber, E | 1 |
| Shear, NH | 1 |
| Diel, IJ | 5 |
| Bartl, R | 1 |
| Burckhardt, P | 4 |
| Fleisch, H | 1 |
| Kyle, RA | 1 |
| Mundy, GR | 1 |
| Sims, EC | 1 |
| Rogers, PB | 1 |
| Besser, GM | 1 |
| Plowman, PN | 1 |
| Leff, R | 1 |
| Glück, S | 1 |
| Stewart, JF | 1 |
| Costello, S | 1 |
| Kennedy, I | 1 |
| Thürlmann, B | 1 |
| Coleman, R | 1 |
| Lacombe, D | 1 |
| Tubiana-Hulin, M | 1 |
| Bastit, P | 1 |
| Wildiers, J | 1 |
| Michel, J | 1 |
| Leonard, R | 1 |
| Nortier, J | 1 |
| Mignolet, F | 1 |
| Hsu, T | 1 |
| Nakaguchi, K | 1 |
| Furukawa, J | 1 |
| Shingai, T | 1 |
| Azama, T | 1 |
| Yoshioka, S | 1 |
| Katsumoto, Y | 1 |
| Morimoto, T | 1 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Hortobagyi, G | 2 |
| Weeks, JC | 1 |
| Desch, CE | 1 |
| Smith, TJ | 1 |
| Senaratne, SG | 1 |
| Pirianov, G | 1 |
| Mansi, JL | 1 |
| Arnett, TR | 1 |
| Colston, KW | 1 |
| Kusama, M | 2 |
| Kaise, H | 2 |
| Nakayama, S | 2 |
| Ota, D | 2 |
| Aoki, T | 2 |
| Koyanagi, Y | 2 |
| Matsunaga, T | 1 |
| Nakamura, Y | 1 |
| Solomayer, EF | 2 |
| Bastert, G | 2 |
| Jin, M | 1 |
| Yang, B | 1 |
| Lei, L | 1 |
| Taniguchi, H | 2 |
| Louviaux, I | 1 |
| Kitazawa, S | 1 |
| Fromigue, O | 1 |
| Lagneaux, L | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Nihei, M | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Abe, R | 1 |
| Nikolic-Tomasević, Z | 1 |
| Jelic, S | 1 |
| Popov, I | 1 |
| Radosavljević, D | 1 |
| Morley, W | 1 |
| Dreicer, R | 1 |
| Kuross, SA | 1 |
| Massoudi, S | 1 |
| Brenner, W | 1 |
| Czech, N | 1 |
| Kampen, WU | 1 |
| Henze, E | 1 |
| Markowitz, GS | 1 |
| Appel, GB | 1 |
| Fine, PL | 1 |
| Fenves, AZ | 1 |
| Loon, NR | 1 |
| Jagannath, S | 1 |
| Kuhn, JA | 1 |
| Dratch, AD | 1 |
| D'Agati, VD | 1 |
| Johnston, SR | 1 |
| Beusterien, KM | 1 |
| Hill, MC | 1 |
| Ackerman, SJ | 1 |
| Zacker, C | 1 |
| Ali, SM | 1 |
| Esteva, FJ | 1 |
| Knight, R | 1 |
| Jones, J | 1 |
| Mercadante, S | 1 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| Dabbene, M | 1 |
| Suzuma, T | 1 |
| Yoshimasu, T | 1 |
| Naito, Y | 1 |
| Janssen van Doorn, K | 1 |
| Neyns, B | 1 |
| Van der Niepen, P | 1 |
| Verbeelen, D | 1 |
| Yokoyama, H | 1 |
| Nakatsuka, K | 1 |
| Shoji, T | 1 |
| Kawasaki, I | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Stajszczyk, M | 1 |
| Mykała-Cieśla, J | 1 |
| Misaka, T | 1 |
| Matunaga, T | 1 |
| Marcus, CS | 1 |
| Saeed, S | 1 |
| Mlikotic, A | 1 |
| Mishkin, F | 1 |
| Pham, HL | 1 |
| Javellana, T | 1 |
| Diestelhorst, S | 1 |
| Minami, C | 1 |
| Adam, Z | 1 |
| Dardoufas, CE | 1 |
| Antypas, CE | 1 |
| Sandilos, PH | 1 |
| Matsopoulos, GK | 1 |
| James, I | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Zwinderman, AH | 2 |
| Aaronson, NK | 1 |
| van Emmerik, B | 1 |
| van Dam, FS | 1 |
| van den Bos, B | 1 |
| Dodwell, DJ | 3 |
| Abbas, SK | 1 |
| Morton, AR | 2 |
| Daley-Yates, PT | 1 |
| Pongchaidecha, M | 1 |
| Thiébaud, D | 3 |
| Leyvraz, S | 1 |
| von Fliedner, V | 2 |
| Perey, L | 2 |
| Cornu, P | 1 |
| Thiébaud, S | 1 |
| Warrell, RP | 1 |
| Jaeger, P | 1 |
| Cantwell, B | 1 |
| Harris, AL | 1 |
| Harinck, HI | 1 |
| Vermey, P | 1 |
| Elte, JW | 1 |
| Borkowski, A | 2 |
| Cleeren, A | 1 |
| Cantrill, JA | 1 |
| Pillai, GV | 1 |
| McMahon, A | 1 |
| Anderson, DC | 1 |
| Williams, MR | 1 |
| Mohajer, MP | 1 |
| Woll, PJ | 1 |
| Miles, M | 1 |
| Scrivener, W | 1 |
| Rischin, D | 1 |
| Bishop, JF | 1 |
| Glibert, F | 1 |
| Nejai, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.[NCT02439112] | 102 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone[NCT00760370] | Phase 2 | 60 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)[NCT05534321] | Phase 1/Phase 2 | 74 participants (Anticipated) | Interventional | 2022-08-29 | Recruiting | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
47 reviews available for pamidronate and Breast Neoplasms
| Article | Year |
|---|---|
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; | 2013 |
Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Gl | 2009 |
Osteonecrosis or metastases of the jaw or both? Case report and review of the literature.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dipho | 2010 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clini | 2010 |
Bisphosphonates as anticancer therapy for early breast cancer.
Topics: Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Proliferation; Clodronic Acid; D | 2010 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinica | 2011 |
[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Ne | 2011 |
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion | 2011 |
[Pamidronate in the treatment of bone metastases from breast cancer].
Topics: Ambulatory Care; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; D | 2002 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycopr | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
Management of bone metastases in breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clin | 2004 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Respons | 2005 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chem | 2005 |
Should oral bisphosphonates be standard of care in women with early breast cancer?
Topics: Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphospho | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind | 2005 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fracture | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2008 |
Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercal | 1994 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms | 1995 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article.
Topics: Analgesia; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonate | 1996 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon | 1996 |
Bisphosphonate therapy in metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; D | 1996 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
Bisphosphonates in clinical oncology. The development of pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Diseases; Bone Neoplasms | 1999 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Bisphosphonates and breast carcinoma: present and future.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pamidronate | 2000 |
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Pamidrona | 2000 |
[Bisphosphonate for treatment of advanced breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as | 2000 |
[Therapeutic value of aredia in treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Palliative | 2000 |
Systemic treatment of metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inh | 2001 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 2000 |
[Bisphosphonates in the treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Hum | 2001 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Bone metastases and breast cancer.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin | 1985 |
60 trials available for pamidronate and Breast Neoplasms
| Article | Year |
|---|---|
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne | 2014 |
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplas | 2016 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collage | 2008 |
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; H | 2009 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; | 2011 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fea | 2013 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycopr | 2003 |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Dose-Respo | 2003 |
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imida | 2002 |
Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessmen
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Fo | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Re | 2004 |
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Topics: Bone Neoplasms; Breast Neoplasms; Canada; Diphosphonates; Double-Blind Method; Female; Humans; Imida | 2004 |
Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Greece; Huma | 2004 |
[Pamidronate in treatment of pain caused by bone metastasis].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Fem | 2004 |
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calc | 2005 |
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb | 2005 |
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Br | 2006 |
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agen | 2008 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Cre | 2007 |
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2008 |
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Bone Neoplasms; Bre | 1994 |
Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1994 |
Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; | 1994 |
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; | 1993 |
Intravenous pamidronate: infusion rate and safety.
Topics: Adult; Aged; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Ad | 1994 |
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Progre | 1994 |
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Topics: Adult; Breast Neoplasms; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; | 1994 |
Disodium pamidronate in the treatment of bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans | 1993 |
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
Topics: Activities of Daily Living; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relation | 1994 |
Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans | 1995 |
Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Monitoring; Female; Hum | 1995 |
Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Topics: Adult; Aged; Analysis of Variance; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitriol; Ca | 1995 |
Metabolic effects of pamidronate in patients with metastatic bone disease.
Topics: Aged; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Development; Bone Neoplasms; Bone | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Mi | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Fr | 1996 |
Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Pa | 1996 |
Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pain; Pamidronate; Qua | 1996 |
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
Topics: Biomarkers, Tumor; Bone Diseases; Breast Neoplasms; Collagen; Diphosphonates; Female; Humans; Male; | 1997 |
Fitting new modalities into practice guidelines.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Data Interpretation, Statis | 1997 |
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Alkaline Phosphatase; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1998 |
[Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1998 |
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Disea | 1999 |
Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Canada; Cancer Care Facilities | 1999 |
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; | 2000 |
Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
[The evaluation of pamidronate therapy for bone metastases from breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2000 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neop | 2001 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imid | 2001 |
Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphospho | 2002 |
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphos | 1991 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph | 1987 |
134 other studies available for pamidronate and Breast Neoplasms
| Article | Year |
|---|---|
Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics.
Topics: Autoantigens; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Pamidronate; Proteomics; Temozolom | 2023 |
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosum | 2020 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medic | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as To | 2017 |
Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hypercalcemia; K | 2018 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tum | 2014 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Hu | 2014 |
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; C | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Antitumor activity of pamidronate in breast cancer cells transformed by low doses of α-particles and estrogen in vitro.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; Cell Line, Tumor; Cel | 2015 |
White Knuckling.
Topics: Adaptation, Psychological; Aged; Antineoplastic Agents; Attitude to Death; Bone Neoplasms; Breast Ne | 2016 |
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2016 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl | 2008 |
Bisphosphonate-associated osteonecrosis of the jaw: successful treatment at 2-year follow-up.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Debrideme | 2008 |
Numb chin syndrome by biphosphonates.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Chin; Diphosphonates; Female; Humans; Hype | 2008 |
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comorbidi | 2010 |
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Hu | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
[A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Maxil | 2010 |
Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms | 2011 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Bre | 2010 |
Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cytotoxicity, Immunologic; Dip | 2010 |
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Ne | 2011 |
Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Glomerulosclerosis, Focal S | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti | 2011 |
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Di | 2012 |
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
[Uterine and ovarian metastases 28 years after the discovery of breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Carcinoma, L | 2003 |
[Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Br | 2003 |
Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neopla | 2004 |
Podocyte injury associated glomerulopathies induced by pamidronate.
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis | 2004 |
Tests for multivariate recurrent events in the presence of a terminal event.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Computer Simulation; Data Interpretation, S | 2004 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; I | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
[Effective weekly paclitaxel therapy for massive metastatic breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; D | 2004 |
Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.
Topics: Antimetabolites; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chi-Square Distribution; C | 2004 |
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Br | 2004 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model.
Topics: Amino Acids; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Cell Line, T | 2004 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort | 2005 |
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Calcium Metabolism Disorders; Chem | 2005 |
Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Clodronic Acid; | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis | 2005 |
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone R | 2005 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplas | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cycl | 2007 |
Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosph | 2006 |
Bisphosphonate-associated arthritis.
Topics: Arthritis; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female | 2006 |
[The incidence and management of bone metastasis from breast cancer].
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fol | 2006 |
[Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2006 |
Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Breech Presentation; Cesarean Sectio | 2006 |
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Crea | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clodronic Acid; Diphospho | 2007 |
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administrat | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Dipho | 2008 |
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Di | 2007 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphospho | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Stu | 2008 |
Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Ag | 2008 |
Progress in the treatment and palliation of advanced breast cancer. Symposium proceedings. Jerusalem, 1993.
Topics: Androstenedione; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; F | 1994 |
The role of pamidronate.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1994 |
Effects of two novel bisphosphonates on bone cells in vitro.
Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Med | 1994 |
[Results of using Aredia for hypercalcemia in oncology patients].
Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Evaluation; Female; Humans; Hypercal | 1993 |
Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalc | 1993 |
[Disodium pamidronate (APD) in the treatment of bone metastases].
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Middle Aged; Multiple Myeloma; Pain | 1993 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate.
Topics: Adult; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Infant, Newbo | 1996 |
Bisphosphonates in the treatment of bone diseases.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Fr | 1996 |
Bisphosphonates spearhead new approach to treating bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; G | 1997 |
Breast cancer and osteolytic metastases: can bisphosphonates help?
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Infusions, Intravenous; Pamidronat | 1997 |
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Biomarkers; Bone Neoplasms; Bone Resorption; Breast | 1997 |
[Bone metastases responsive to pamidronate therapy in breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonat | 1997 |
Pamidronate and metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pain Management; Pamidronate | 1997 |
Pamidronate and metastatic breast cancer.
Topics: Antineoplastic Agents; Bias; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamid | 1997 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhes | 1997 |
A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Diphosphonates; Female; | 1997 |
Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Pamidronate | 1997 |
Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Diphosphonates; | 1998 |
[A case of osteolytic metastases from breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr | 1998 |
Pain relief and sclerosis of bone metastases in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: which treatment helped?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mod | 1998 |
Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization.
Topics: Adult; Amino Acids; Animals; Biomarkers; Bone Resorption; Breast Neoplasms; Calcium; Cell Adhesion; | 1998 |
Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management.
Topics: Adult; Alendronate; Antineoplastic Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Hy | 1998 |
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Bisphosphonates for metastatic bone pain.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; | 1999 |
Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Breast Neopl | 1999 |
[A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1999 |
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Dise | 2000 |
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clod | 2000 |
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clod | 2000 |
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clod | 2000 |
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clod | 2000 |
[Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcitonin; Consciousness Disorders; Diphos | 2000 |
[Treatment of metastatic bone pain with Aredia(Pamidronate)].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Breast Neop | 1998 |
[A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr | 2000 |
[Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2000 |
Bisphosphonates induce breast cancer cell death in vitro.
Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspa | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasm | 2001 |
[Bone scintigraphy in the control of bone metastasis of breast cancer during pamidronate and tamoxifen combination therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 2001 |
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis, Focal Seg | 2001 |
The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fema | 2001 |
Bisphosphonates may be useful in treatment of bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials a | 2001 |
Pamidronate in incident pain due to bone metastases.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphona | 2001 |
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.
Topics: Adult; Breast Neoplasms; Diphosphonates; Female; Humans; Lung Neoplasms; Osteoarthropathy, Secondary | 2001 |
Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Nephr | 2001 |
[Intravenous pamidronate delivery to a case with multiple bone metastasis of breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; | 2001 |
[A case of breast cancer with multiple bone metastases that responded remarkably to doxifluridine (5'-DFUR), cyclophosphamide (CPA), medroxyprogesterone acetate (MPA) and pamidronate disodium therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2002 |
Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Interactions; Drug Therapy, C | 2002 |
[Is pamidronate or clodronate better?].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Hum | 2002 |
Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Topics: Administration, Oral; Adult; Amino Acids; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium | 1992 |
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hy | 1991 |
The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Biological Availability; Bone Neoplasms; Breast Neoplasms; Diphosphonat | 1991 |
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; D | 1991 |
The measurement of change of quality of life in clinical trials.
Topics: Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Models, Statistical; Mul | 1990 |
Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug E | 1990 |
Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Topics: Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Diphosphonates; Female; Humans; | 1990 |
Pamidronate and hypercalcaemia of malignancy.
Topics: Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Evaluation; Female; Humans; Hyperc | 1989 |
Treatment of tumor-induced osteolysis by APD.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1989 |
Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemi | 1986 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Infusions, Intravenous; Os | 1988 |
Lytic bone metastases after APD in breast carcinoma.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1988 |
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Middle Aged; Pamidron | 1988 |
Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD)
Topics: Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Middl | 1988 |
[Bone metastases and hypercalcemia in cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 1988 |
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hydroxyprolin | 1987 |